A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
Clinical and Translational Medicine2021Vol. 11(3), pp. e346–e346
Citations Over TimeTop 10% of 2021 papers
Chunrui Li, Wenyue Cao, Yimei Que, Qiuxiang Wang, Yi Xiao, Chaojiang Gu, Di Wang, Jue Wang, Lijun Jiang, Hao Xu, Jinhuan Xu, Xiaoxi Zhou, Zhenya Hong, Na Wang, Liang Huang, Shangkun Zhang, Liting Chen, Xia Mao, Min Xiao, Wei Zhang, Meng Li, Yang Cao, Tongcun Zhang, Li J, Jianfeng Zhou
Abstract
Anti-BCMA CAR T cell treatment is safe and highly active in R/R multiple myeloma.
Related Papers
- → Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome(2019)320 cited
- → <p>Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy</p>(2019)137 cited
- → Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy(2019)76 cited
- → Early and Late Toxicities of Chimeric Antigen Receptor T-Cells(2023)10 cited
- Combined fludarabine and cyclophosphamide pretreatment alleviated acute graft-versus-host disease(2009)